Approximately 15–20% of all breast cancers are of triple-negative BC (TNBC) subtype, which displays negative immuno-histochemical expression patterns of hormone receptors (estrogen receptor (ER), progesterone receptor (PR)), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and breast cancer.